# Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL

> **NCT06863259** · PHASE1 · RECRUITING · sponsor: **Children's Hospital Medical Center, Cincinnati** · enrollment: 28 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone

## Key facts

- **NCT ID:** NCT06863259
- **Lead sponsor:** Children's Hospital Medical Center, Cincinnati
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-21
- **Primary completion:** 2028-01-01
- **Final completion:** 2029-01-01
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06863259

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06863259, "Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06863259. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*